Medical (incl. medical device & pharma), US Foreign Corrupt Practices Act & Dodd Frank - Written by on Tuesday, November 23, 2010 3:23 - 0 Comments

Pharmaceutical businesses and the stark warning from the SFO

Print Friendly

Barry and Richard write on FCPA Compliance and Ethics Blog about the thinly veiled warning recently issued by the Director of the Serious Fraud Office, Richard Alderman to the pharmaceutical sector.

It has been well publicised that the pharmaceutical sector has been under increasing scrutiny from US regulators. Mr. Alderman spoke at a UK pharmaceutical conference about the industry, the Bribery Act and the SFO’s close co-operation with the US Department of Justice which is involved in a Foreign Corrupt Practices Act investigation into the pharmaceutical sector in the US.

Share Button


Comments are closed.

Brought to you by...

Barry Vitou &
Richard Kovalevsky Q.C.

The views expressed on this website are those of Barry Vitou & Richard Kovalevsky QC and/or our guest authors from time to time. Please see our terms of use

Our Tweets

Monday, July 23, 2018 10:03

UK Court rules a suspect in a criminal investigation has reasonable expectation it will be kept private… https://t.co/CaV8n2VLsu

Monday, June 25, 2018 14:08

Roll up, roll up…House of Lords Bribery Act Committee calls for evidence on Bribery Act & Deferred Prosecution Agre… https://t.co/7G3eXKbT7O

Wednesday, June 6, 2018 9:13

Opinion: New Serious Fraud Office Director Appointment reflects Americanisation of UK Corporate Crime Enforcement a… https://t.co/F7pRFyNPZy

Monday, May 21, 2018 7:21

Lords to review Bribery Act over its burden on SMEs via @FT
https://t.co/udoKSqP8xa